As Tocagen heads into a reverse merger with privately held Forte Biosciences, San Diego-based Denovo Biopharma swooped in to snap up that company’s retroviral replicating vector platform (RRV), including an asset that stumbled in a Phase III study that Denovo believes still has some life.